The phase 3 MONARCH 2 study evaluating women with HR-positive/HER2-negative advanced breast cancer showed a higher incidence of infection in the abemaciclib arm (42.6%) than it did in the placebo arm (24.7%). Here, ERBB2 is linked to breast carcinoma.